Please click any of the icons
below to follow St. Luke's in
the world of Social Media.
43309 US Highway 19 N
Tarpon Springs, FL 34689
Toll Free: 800.282.9905
13303 N Dale Mabry Highway
Tampa, FL 33618
1180 Mariner Boulevard
Spring Hill, FL 34609
14030 US Hwy 19 N
Bayonet Point, FL 34667
9400 9th Street N (MLK)
St. Petersburg, FL 33702
If you are interested in any of the services St. Luke's provides, contact our Florida practice by filling out the form below.
Brian A. Phillpotts, MD, Raymond T. Agia, MD and BJ Ahn, MD specialize in retina treatment and eye surgery at our Tampa Bay area offices. They have experience helping patients with a full range of vitreous and retina problems, including diabetic retinopathy, macular degeneration, retinal detachment, macular holes, and other vitreoretinal disorders. Drs. Phillpotts, Agia and Ahn are committed to providing patients with exemplary vision care.
Macular degeneration is the number one cause of legal blindness in people over the age of 60. Patients between the ages of 64 and 74 have a one-in-four chance of developing macular degeneration. At age 75, the chances increase to one-in-three. Since Macular Degeneration can be hard to detect in its early stages, it is important for seniors to undergo regular comprehensive eye exams. If an exam reveals that you do have this disease, the retinal team at St. Luke’s may recommend one or a combination of several treatment options.
LUCENTIS™ is FDA and Medicare approved for the treatment of neovascular (wet) age-related macular degeneration (AMD), a leading cause of blindness in people over 55. In wet AMD, new blood vessels grow under the retina and leak blood and fluid causing rapid damage to the macula, the portion of the eye responsible for fine, detailed central vision. Though it is not a cure for the disease, LUCENTIS™, by slowing or stopping the formation of these blood vessels, may help slow vision loss and may preserve remaining eyesight. Our retina specialist can discuss this treatment in detail and help determine if it is right for you.
AVASTIN® is another drug that helps to slow the growth of new blood vessels. Approved by the FDA to treat colon cancer, it is also used to combat age related "wet" macular degeneration, which is caused by abnormal blood vessel growth in the retina. The goal of treatment is to prevent further loss of vision. Although some patients have regained vision, the medication may not restore vision that has already been lost, and may not ultimately prevent further loss of vision caused by the disease. After the pupil is dilated and the eye is numbed with anesthesia, the medication is injected into the vitreous, or jelly-like substance in the back chamber of the eye. AVASTIN® is administered by an injection into your eye as needed at regular intervals (about every four to six weeks); your ophthalmologist will tell you how often you will receive the injection, and for how long. Contact our eye surgeons for more information about this treatment.
MACUGEN® is also a treatment option for patients with wet age-related macular degeneration (AMD). MACUGEN® works by blocking a signal that causes abnormal blood vessels to grow and leak. Though it is not a cure for the disease, it may help slow vision loss and may preserve remaining eyesight. Contact St. Luke's for more information about MACUGEN®.
Diabetes can cause changes in the retina that can seriously threaten vision. The adverse changes are known as diabetic retinopathy. If you have diabetes, our eye surgeons can closely monitor your vision for early detection of problems. They can evaluate symptoms such as blurred vision, floaters, and sudden vision loss, which are often signs of the disease. If diabetic retinopathy has advanced to a stage which requires treatment, our eye surgeons can discuss your options with you.